BIOA — BioAge Labs, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1709941 ·
Last close
$16.61
Market Cap
$738.36M
52W High
$23.00
52W Low
$14.73
ADV30
398,033
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,772,000 | — | -25,375,000 | -22,253,000 | 397,654,000 | 241,777,000 | 18,533,000 |
| Dec 2025 | 3,078,000 | — | -28,423,000 | -25,943,000 | 294,889,000 | 188,888,000 | 22,838,000 |
| Sep 2025 | 2,054,000 | — | -23,140,000 | -20,171,000 | 305,090,000 | 215,573,000 | 27,626,000 |
| Jun 2025 | 2,412,000 | — | -24,771,000 | -21,563,000 | 322,148,000 | 220,330,000 | 27,367,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,627,000
Investing CF
$-95,216,000
Financing CF
$11,469,000
CapEx
$-719,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.22
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-333,416,000
Inventory
—
Receivables
$769,000
ST Investments
$92,210,000
EBIT TTM
$-79,908,000
Pretax Income TTM
$-80,605,000
Interest Exp TTM
$697,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,316,000
EBITDA
$-101,470,000
Free Cash Flow
$-58,337,752
Enterprise Value
$359,199,904
Total Cash
$383,193,984
Total Debt
$4,034,000
Shares Out
44,452,734
Trailing EPS
$-2.40
Book Value
$8.54
ROE
-26.0%
ROA
-17.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 8,995,000 | -92,780,000 | -80,605,000 | 294,889,000 | 22,838,000 | — | -81,627,000 |
| Dec 2024 | 0 | -78,194,000 | -71,109,000 | 358,234,000 | 35,107,000 | — | -51,522,000 |
| Dec 2023 | 0 | -48,400,000 | -63,854,000 | 25,924,000 | 199,320,000 | — | -37,362,000 |
| Dec 2022 | 0 | -39,969,000 | -39,722,000 | 28,429,000 | 140,988,000 | — | -36,181,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.71
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLMD | RELMADA THERAPEUTICS, INC. | $738.43M | $7.04 | — |
| ANRO | Alto Neuroscience, Inc. | $744.69M | $21.22 | — |
| CYRX | Cryoport, Inc. | $705.63M | $14.00 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $700.74M | $33.26 | — |
| ANL | Adlai Nortye Ltd. | $700.12M | $11.92 | — |
News headlines (Yahoo Finance, 1h cache)
BioAge Labs to Present at Upcoming Investor Conferences
2026-05-22 13:00 · Yahoo
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?
2026-05-20 20:43 · Yahoo
This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday
2026-05-13 17:43 · Yahoo
AMD, Under Armour downgraded: Wall Street's top analyst calls
2026-05-13 13:35 · Yahoo
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33
2026-05-13 12:47 · Yahoo
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More
2026-05-13 11:54 · Yahoo
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
2026-05-08 19:12 · Yahoo
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-08 13:00 · Yahoo
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
2026-05-04 20:30 · Yahoo
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
2026-04-24 16:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.